stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) EV/FCF
As of 5 November 2026, Adaptive Biotechnologies Corporation (ADPT) trades at a EV/FCF of −494×. Over the past ten years it has ranged from −547× (October 2026) to 16.4× (October 2019); the current reading is higher than 0% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −50.2× | — |
| FY2024 | −8.9× | — |
| FY2023 | −3.4× | — |
| FY2022 | −4.2× | — |
| FY2021 | −14.5× | — |
| FY2020 | −42.6× | — |
| FY2019 | 7.9× | 424.30% |
| FY2018 | 1.5× | 0.00% |
| FY2017 | 1.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −530× | — |
| Jun 2026 | −142× | — |
| Mar 2026 | −73.1× | — |
| Dec 2025 | −50.2× | — |
| 29 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ADPT Adaptive Biotechnologies Corporation | −494× |
| NEO NeoGenomics, Inc. compare | −96.9× |
| WGS GeneDx Holdings Corp. compare | −25.0× |
| GRAL GRAIL, Inc. compare | −15.9× |
| VCYT Veracyte, Inc. compare | 9.0× |
| SHC Sotera Health Company compare | 47.0× |
| CDNA CareDx, Inc. compare | 64.7× |
| BLLN BillionToOne, Inc. compare | 142× |
| RDNT RadNet, Inc. compare | 208× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement